Remarkably, SAR405 (Vps34i) reversed the various NAFLD protective effects of rAAV-TRABID, including the reduction in liver/body weight, hepatic lipid content, and serum levels of AST and ALT (Fig. 8b–e and Supplementary Fig. 7d). This evidence concerns the gene ZRANB1 and metabolic dysfunction-associated steatotic liver disease.